Table 4. Antibiotic susceptibility pattern of Gram-negative bacterial isolates in pus samples.
|
Antibiotics |
Pseudomonas spp. (n=368) |
Proteus spp. (n=95) |
E. coli (n=93) |
Klebsiella spp. (n=64) |
Acinetobacter spp. (n=6) |
Enterobacter spp. (n=1) |
||||||
|
R |
S |
R |
S |
R |
S |
R |
S |
R |
S |
R |
S |
|
|
AK (%) |
47 (12.7) |
292 (79.3) |
1 (1.0) |
90 (94.7) |
25 (26.8) |
67 (72) |
21 (32.8) |
27 (42.1) |
- |
6 (100) |
|
1 (100) |
|
AMC (%) |
222 (60.3) |
27 (7.3) |
81 (85.2) |
8 (8.4) |
93 (100) |
- |
22 (34.3) |
28 (43.7) |
6 (100) |
|
- |
- |
|
AZM (%) |
133 (36.1) |
156 (42.3) |
8 (8.4) |
3 (3.1) |
67 (72.0) |
26 (27.9) |
23 (35.9) |
28 (43.7) |
6 (100) |
|
- |
|
|
CAZ (%) |
260 (70.6) |
39 (10.5) |
88 (92.6) |
- |
67 (72.0) |
- |
14 (21.8) |
- |
6 (100) |
|
- |
|
|
CFM (%) |
(79.6) |
4 (1) |
88 (92.6) |
1 (1) |
67 (72.0) |
26 (27.9) |
49 (76.5) |
6 (9.3) |
6 (100) |
|
1 (100) |
|
|
CH (%) |
207 (56.2) |
63 (17.1) |
79 (83.1) |
4 (4.2) |
67 (72.0) |
- |
45 (70.3) |
12 (18.7) |
6 (100) |
|
1 (100) |
|
|
CT (%) |
218 (59.2) |
56 (16) |
17 (17.8) |
3 (3.1) |
36 (38.7) |
- |
56 (87.5) |
5(7.8) |
6 (100) |
|
1 (100) |
|
|
CTR (%) |
292 (79.3) |
22 (5.9) |
79 (83.1) |
3 (3.1) |
67 (72.0) |
25 (26.8) |
34 (53.1) |
15 (23.4) |
6 (100) |
|
- |
|
|
CXM (%) |
213 (57.8) |
36 (9.7) |
85 (89.4) |
1 (1) |
67 (72.0) |
- |
34 (53.1) |
1 (1.5) |
6 (100) |
|
- |
|
|
CIP (%) |
89 (24.1) |
194 (52.7) |
8 (8.4) |
76 (80) |
30 (32.2) |
11 (11.8) |
17 (26.5) |
33 (51.5) |
6 (100) |
|
- |
1 (100) |
|
DA (%) |
233 (63.3) |
38 (10.3) |
85 (89.4) |
1 (1) |
92 (98.9) |
- |
39 (60.9) |
7 (10.9) |
6 (100) |
|
1 (100) |
|
|
FEP (%) |
277 (75.2) |
29 (7.8) |
81 (85.2) |
5 (5.2) |
58 (62.3) |
25 (26.8) |
56 (87.5) |
4 (6.2) |
6 (100) |
|
1 (100) |
|
|
FL (%) |
205 (55.7) |
18 (4.8) |
- |
- |
92 (98.9) |
- |
3 (4.6) |
- |
6 (100) |
|
- |
|
|
GEN (%) |
77 (20.9) |
248 (67.3) |
4 (4.2) |
79 (83.1) |
- |
92 (98.9) |
26 (40.6) |
4 (6.2) |
- |
|
- |
|
|
MEM (%) |
59 (16.0) |
275 (74.7) |
1 (1.0) |
90 (94.7) |
- |
93 (100) |
50 (78.1) |
8 (12.5) |
- |
6 (100) |
1 (100) |
|
|
NIT (%) |
118 (32.0) |
41 (11.1) |
75 (78.9) |
9 (9.4) |
25 (26.8) |
40 (43) |
11 (17.1) |
- |
6 (100) |
|
- |
|
|
LE (%) |
67 (18.2) |
239 (64.9) |
6 (6.3) |
80 (84.2) |
55 (59.1) |
28 (30.1) |
16 (25.0) |
33 (51.5) |
- |
6 (100) |
- |
1 (100) |
|
LNZ (%) |
111 (30.1) |
210 (57) |
78 (82.1) |
10 (10.5) |
92 (98.9) |
- |
11 (17.1) |
48 (75) |
6 (100) |
|
- |
|
|
SXT (%) |
174 (47.2) |
45 (12.2) |
81 (85.2) |
2 (2.1) |
25 (26.8) |
37 (39.7) |
7 (10.9) |
- |
6 (100) |
|
- |
|
|
TE (%) |
172 (46.7) |
80 (21.7) |
8 (8.4) |
6 (6.3) |
56 (60.2) |
- |
42 (65.9) |
10 (15) |
6 (100) |
|
1 (100) |
|
AK=Amikacin, AMC=Amoxicillin, AZM=Azithromycin, CAZ=Ceftazidime, CFM=Cefixime, CH=Cephradine, CT=Cephalexin, CTR=Ceftriaxone, CXM=Cefuroxime, CIP=Ciprofloxacin, DA=Clindamycin, FEP=Cefepime, FL=Fluconazole, GEN=Gentamycin, MEM=Meropenem, NIT=Nitrofurantoin, LE=Levofloxacin, LNZ=Linozolid, SXT=Sulfamethoxazole, TE=Tetracycline. R =Resistance, S =Sensitive.